en · de · es
cjc-1295-notes.peptides6579.com › Topic › Albumin Binding And Duration Of Action — What the Evidence Shows

Albumin Binding And Duration Of Action — What the Evidence Shows

By Editorial Desk · published 2026-07-05 · last reviewed 2026-08-01 · Topic

GHRH receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Albumin Binding and Duration of Action

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Structure And Receptor Pharmacology

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Cjc-1295 at a glance

PropertyValueNotes
Duration with linkerSeveral daysReported in early human work
Duration without linkerTens of minutesShort plasma residence
Albumin attachment siteCysteine-34Covalent maleimide reaction
Primary receptorPituitary GHRH receptorStimulates growth hormone release
Downstream markerInsulin-like growth factor 1Indirect measure of activity

Receptor Action and Clearance

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Related pages on this site

Mechanism and Pharmacokinetics

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

Background and Molecular Design

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Background from the literature

=== Other conditions === Spironolactone has been studied in the treatment of rosacea in both males and females. Spironolactone has been studied in fibromyalgia in women. It has also been studied in bulimia nervosa in women, but was not found to be effective.

== Construction of PAM matrices == PAM matrices were introduced by Margaret Dayhoff in 1978. The calculation of these matrices was based on 1572 observed mutations in the phylogenetic trees of 71 families of closely related proteins. The proteins to be studied were selected on the basis of having high similarity with their predecessors. The protein alignments included were required to display at least 85% identity. As a result, it is reasonable to assume that any aligned mismatches were the result of a single mutation event, rather than several at the same location. Each PAM matrix has twenty rows and twenty columns — one representing each of the twenty amino acids translated by the genetic code. The value in each cell of a PAM matrix is related to the probability of a row amino acid before the mutation being aligned with a column amino acid afterwards. From this definition, PAM matrices are an example of a substitution matrix.

The discovery in 1911 that electrons emitted in beta decay have a continuous rather than a discrete spectrum appeared to contradict conservation of energy, under the then-current assumption that beta decay is the simple emission of an electron from a nucleus. This problem was eventually resolved in 1933 by Enrico Fermi who proposed the correct description of beta-decay as the emission of both an electron and an antineutrino, which carries away the apparently missing energy.

An even more important event was the publication of a book by Regine Claβen-Bockhoff (2024) Die Pflanze: Morphologie, Entwicklung und Evolution von Vielfalt (The Plant: Morphology, Development and Evolution of Diversity). Like Kaplan's book, this book is very comprehensive (over a thousand pages) and beautifully illustrated (she worked with two illustrators), but unlike Kaplan's book, her book presents major conceptual innovations. Although, for the vegetative region, she accepts the categories of classical morphology, contrary to Kaplan, she recognizes that not all structures can be pressed into these categories. For flowers, she abandoned the classical framework altogether. Instead of interpreting the flower as a modified short shoot (as posited by classical morphology), she proposed that flowers are sporangia bearing units so that stamens and carpels are sporangiophores, which are considered 'de novo' structures not necessarily homologous with vegetative leaves. Rolf Sattler proposed an Articulation Morphology. It is based on the open growth of plants, which occurs through ramification that leads to articulation - the formation of articles between successive ramifications or after a single ramification. Thus, the plant is seen as an articulated whole, consisting of articles. The concept of the article encompasses the continuum between morphological categories and different levels of organization, from organ systems to organs, parts of organs and trichomes. Furthermore, it applies to all plants, from algae to bryophytes and vascular plants.

Sources: en.wikipedia.org

Reference notes

=== Iraq === In a March 2000 article in The Guardian, Galloway described himself as a supporter of the Iraqi people and the Ba'ath Party, but not Saddam Hussein himself. In a House of Commons debate on 6 March 2002, Foreign Office minister Ben Bradshaw said Galloway was "not just an apologist, but a mouthpiece, for the Iraqi regime over many years." Galloway called the minister a liar and refused to withdraw on the grounds that Bradshaw's claim was "a clear imputation of dishonour", and the sitting was suspended due to the dispute. Bradshaw later withdrew his allegation, and Galloway apologised for using unparliamentary language. Giving evidence in his libel case against The Daily Telegraph in 2004, Galloway testified that he regarded Saddam as a "bestial dictator" and would have welcomed his removal from power, but not by means of a military attack on Iraq. Galloway also pointed out that he was a prominent critic of Saddam Hussein's government in the 1980s, as well as of the role of Margaret Thatcher's government in supporting arms sales to Iraq during the Iran–Iraq War.

Combined Bisulfite Restriction Analysis (or COBRA) is a molecular biology technique that allows for the sensitive quantification of DNA methylation levels at a specific genomic locus on a DNA sequence in a small sample of genomic DNA. The technique is a variation of bisulfite sequencing, and combines bisulfite conversion based polymerase chain reaction with restriction digestion. Originally developed to reliably handle minute amounts of genomic DNA from microdissected paraffin-embedded tissue samples, the technique has since seen widespread usage in cancer research and epigenetics studies.

== Taxonomy == German naturalist Wilhelm Peters described the coastal taipan as Pseudechis scutellatus in 1867, from material collected in Rockhampton, Queensland. Charles Walter De Vis described Pseudechis wilesmithii from Walsh River in north Queensland in 1911. In 1922, scientific bird collector William McLennan killed two snakes near Coen in far north Queensland. Impressed by their size—up to 2.76 m, he sent the skins and skulls to the Australian Museum in Sydney. Australian naturalist Roy Kinghorn established the genus Oxyuranus in 1923, describing a specimen from Coen as O. maclennani after its collector. He noted the distinctness of the palatine bone necessitated the new genus as distinct from all other elapid snakes. In 1930, Kinghorn announced it as the second largest venomous snake in the world, with 3/4 inch fangs. In 1933, Australian zoologist Donald Thomson concluded that Pseudechis scutellatus and Oxyuranus maclennani were the same species; this meant that Peters' specific epithet had priority, as did Kinghorn's genus as the species was highly distinct. Hence, the coastal taipan became Oxyuranus scutellatus. Thomson had spent some years in Cape York peninsula with the indigenous people, who told tales of a giant snake they greatly feared. Australian herpetologist Ken Slater described Oxyuranus scutellatus canni, commonly known as the Papuan taipan, in 1956, on the basis of its distinctive coloration. He named it after George Cann, longtime Snake Man of La Perouse. It is found throughout the southern portion of the island of New Guinea.

Legio I I Armeniaca I Flavia Constantia (reliable Flavian): comitatensis unit under the command of the Magister militum per Orientis I Flavia Gallicana Constantia (reliable Flavian legion from Gallia): pseudocomitatensis under the command of the Magister Peditum per Gallias. The legion was founded by Constantius I Chlorus. The legions objective was to protect the Armorican coast and fight the Roman-British usurper, Allectus. I Flavia Martis (Flavian legion devoted to Mars): pseudocomitatensis. The legion was founded by Constantius Chlorus to fight Allectus. It was stationed in Gaul. I Flavia Pacis (Flavian legion of peace): comitatensis under the command of the Magister Peditum I Flavia Theodosiana: comitatensis. I Illyricorum (of the Illyrians): stationed at the Camp of Diocletian in Palmyra I Iovia (devoted to Jupiter): levied by Diocletian, stationed at Noviodunum in Scythia Minor I Isaura Sagittaria (archers from Isauria): pseudocomitatensis under the command of the Magister militum per Orientis I Iulia Alpina: pseudocomitatensis under the command of the Magister Peditum in Italy. It is unknown who founded the legion although it was probably Crispus or Constans. I Martia possibly based near modern Kaiseraugst. The Legion could have had the surname Victrix. The legion was probably founded by Diocletian. It also may have built forts in Valeria. I Maximiana Thaebanorum (the Thebans of Maximianus): comitatensis unit stationed near Thebes, Egypt, and probably fighting in the battle of Adrianople I Noricorum (of the Noricans): stationed in Noricum.

=== Safety === Like for other radioactive imaging agents in medicine, the applied amounts of radioactivity are so low that radiation-related adverse effects are very unlikely to occur, and have not been observed in practice. Consistent with the "tracer principle", the amount of pharmacologically active compound injected to a patient in the course of such an examination is extremely low. Adverse events, such as toxicity or allergic reactions, are thus highly improbable. No adverse or clinically detectable pharmacologic effects were observed following intravenous administration of 68Ga-Trivehexin when administered to cancer patients, and there were no significant changes in vital signs, laboratory study results, or electrocardiograms. In a study involving healthy volunteers, researchers again reported no adverse or clinically detectable pharmacologic effects and no significant changes in vital signs.

Sources: en.wikipedia.org

Frequently asked questions

How does the reactive group attach to albumin?

A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.

Does the modification change how the peptide signals?

The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.

Are human half-life figures well established?

Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

Network